Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search span> per sponsor: Institut Jules Bordet
Woman and Man Max 99 years
Institut Jules Bordet - Université Libre de Bruxelles
Update Il y a 5 ans
A study to assess the safety and immunogenicity of an anti leukemia Antigen-Specific Cancer Immunotherapeutic (ASCI) combined with infusions of T lymphocytes in in vivo regulatory T cells depleted patients as post-consolidation therapy for adult patients with WT1-positive Acute Myeloid Leukemia (AML)
Co-primary Objectives : To evaluate the safety of combined treatment strategy of WT1-A10 + AS01B, infusions of ex vivo regulatory T cells depleted T lymphocytes and in vivo regulatory T cells deplet...
Country
None
organs
None
Specialty
None
unknown
More information
Woman Max 99 years
Institut Jules Bordet
Update Il y a 5 ans
Influence of a new model of relative hypoxia on the evolution of erythropoietin and haemoglobin in patients undergoing breast reconstruction by a Deep Inferior Epigastric Perforator Flap
Impact of differents models of relative hypoxia on the erythropoietin, erythrocyte and haemoglobin levels.
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Institut Jules Bordet
Update Il y a 5 ans
A phase II study of doxorubicin, cyclophosphamide and vindesine with valproic acid in patients with refractory or relapsing small cell lung cancer after platinum derivatives and etoposide
To determine 6 months progression-free survival of the combination of doxorubicin, cyclophosphamide and vindesine (VdsAC) plus valproic acid in patients with refractory SCLC after treatment with plati...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man
Between 18 years
and 99 years
Institut Jules Bordet
Update Il y a 5 ans
Étude KIARA : étude de phase 2 visant à déterminer le bénéfice clinique du trastuzumab emtansine chez des patientes ayant un cancer du sein positif pour HER2 métastatique avec des métastases cérébrales.
Le cancer du sein prend naissance dans les cellules du sein mais il peut aussi envahir les tissus voisins et former des métastases dans d’autres parties du corps. La surexpression de HER2 est liée à d...
Country
France
organs
Sein
Specialty
Immunothérapie - Vaccinothérapie
,
Imagerie
Essai abandon
More information
Woman Max 99 years
Institut Jules Bordet
Update Il y a 5 ans
Neoadjuvant Biomarker ResearcH Study of Palbociclib Combined with Endocrine Therapy in Estrogen Receptor Positive/ HER2 Negative Breast CAncer
• To identify biomarkers of resistance to a 4-month preoperative treatment of palbociclib plus endocrine therapy defined as stable or progressive disease by ultrasound (based on WHO criteria) using RN...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Institut Jules Bordet
Update Il y a 5 ans
Imaging of head and neck tumors and their associated lymph nodes after intravenous injection of Indocyanine Green, a fluorescent molecule
Definition of the distribution of intravenously injected ICG in the normal and pathological lymph nodes draining the dissected tumor in head and neck cancer patients or in nodes recurrences in head an...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Institut Jules Bordet
Update Il y a 5 ans
Randomised Phase II study of biweekly versus fractionated triweekly combination Taxotere-Cisplatin-5FU in advanced gastric and gastro-esophageal junction cancer
evaluate toxicity of a biweekly and a fractionated triweekly regimen of Taxotere-Cisplatin-5FU in advanced gastric and oesogastric junction cancer
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman Max 99 years
Institut Jules Bordet
Update Il y a 5 ans
A non randomized , stratified phase II trial evaluating efficacy and safety of oxaliplatin in combination with 5-Fluorouracil in patients with platinum-sensitive and platinum-resistant recurrent ovarian carcinoma
to assess objective response rate
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Institut Jules Bordet
Update Il y a 5 ans
The use of isotope-bound antibodies to visualize and subsequently treat B-cell lymphoma
Evaluation of safety of Zirconium-89 (89Zr)- rituximab chimeric anti-CD20 antibody for PET/CT imaging and dosimetry. Evaluation of safety of Yttrium-90 (90Y)-rituximab chimeric anti-CD20 antibody radi...
Country
None
organs
None
Specialty
None
unknown
More information
Woman Max 99 years
Institut Jules Bordet
Update Il y a 5 ans
A study evaluating the effect of a chemotherapy regimen on the menstrual and ovarian functions of young breast cancer patients
- Evaluate the impact of a cyclophosphamide-free regimen on the ovarian function recovery defined as menstrual resumption within 12 months following the end of chemotherapy - Evaluate the impact of a ...
Country
None
organs
None
Specialty
None
Closed trial
More information
1
2
Next